Gainers
- CERo Therapeutics Hldgs CERO stock increased by 71.0% to $0.32 during Friday’s pre-market session. The company’s market cap stands at $48.1 million.
- QT Imaging Holdings QTI shares moved upwards by 18.58% to $0.58. The company’s market cap stands at $12.4 million. As per the news, the Q3 earnings report came out 2 days ago.
- TC BioPharm (Holdings) TCBP shares rose 18.02% to $0.77.
- Alpha Teknova TKNO stock rose 14.17% to $7.49. The market value of their outstanding shares is at $399.2 million.
- Gain Therapeutics GANX shares rose 14.04% to $1.99. The market value of their outstanding shares is at $50.8 million. As per the news, the Q3 earnings report came out yesterday.
- iSpecimen ISPC stock increased by 14.02% to $4.96. The market value of their outstanding shares is at $4.7 million.
Losers
- TFF Pharmaceuticals TFFP shares fell 71.9% to $0.45 during Friday’s pre-market session. The market value of their outstanding shares is at $1.5 million.
- Eyenovia EYEN shares decreased by 60.02% to $0.14. The market value of their outstanding shares is at $11.6 million. As per the news, the Q3 earnings report came out 3 days ago.
- Akoya Biosciences AKYA stock declined by 31.31% to $2.15. The market value of their outstanding shares is at $106.4 million. As per the news, the Q3 earnings report came out yesterday.
- GRI Bio GRI shares declined by 20.85% to $0.76. The market value of their outstanding shares is at $2.8 million. As per the news, the Q3 earnings report came out yesterday.
- Tivic Health Systems TIVC shares declined by 17.66% to $0.3. The company’s market cap stands at $1.8 million. As per the press release, Q3 earnings came out yesterday.
- Carmell CTCX shares decreased by 13.44% to $0.24. The company’s market cap stands at $5.1 million. As per the news, the Q3 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.